Abstract
BackgroundDarpp-32 and t-Darpp are expressed in several forms of breast cancer. Both are transcribed from the gene PPP1R1B via alternative promoters. In humans, Darpp-32 is expressed in both normal and malignant breast tissue, whereas t-Darpp has only been found in malignant breast tissue. The exact biological functions of these proteins in the breast are not known. Although Darpp-32 is a well known regulator of neurotransmission, its role in other tissues and in cancer is less well understood. t-Darpp is known to increase cellular growth, inhibit apoptosis and contribute to acquired drug resistance. The use of transgenic mouse mammary tumor models to study Darpp-32 and t-Darpp in breast cancer in vivo has been limited by a lack of knowledge regarding t-Darpp expression in mice, in both normal and malignant tissue.MethodsWe used RT-PCR and Western analysis to investigate Darpp-32 and t-Darpp levels in normal and malignant mouse mammary tissue. To determine if Darpp-32 and t-Darpp play a direct role in mammary tumor development, Ppp1r1b gene knockout mice and wild-type mice were crossed with a mouse mammary tumor model. Tumor growth and metastasis were examined. Differences between groups were determined by the two-tailed Student’s t-test.ResultsWe found that Darpp-32 was expressed in normal mouse mammary tissue and in some breast tumors, whereas t-Darpp was found exclusively in tumors, with t-Darpp usually expressed at equal or higher levels than Darpp-32. Ppp1r1b knockout in MMTV-PyMT transgenic tumor mice resulted in a decrease in tumor growth.ConclusionsThe shift in expression from Darpp-32 to t-Darpp during mouse mammary tumorigenesis is reminiscent of the expression patterns observed in humans and is consistent with a role for t-Darpp in promoting cell growth and Darpp-32 in inhibiting cell growth. Decreased tumor growth in Ppp1r1b knockout mice also suggests that t-Darpp plays a direct role, predominant to Darpp-32, in mammary tumor development. These results indicate that transgenic mouse mammary tumor models might be valuable tools for future investigation of Darpp-32 and t-Darpp in breast cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/1476-4598-13-192) contains supplementary material, which is available to authorized users.
Highlights
Darpp-32 and truncated Darpp-32 (t-Darpp) are expressed in several forms of breast cancer
The purpose of this study was to determine if Darpp-32 and t-Darpp are expressed in mouse mammary tissue and to see if their expression patterns are similar between humans and mice
Darpp-32, but not t-Darpp, is expressed in normal mouse mammary tissue In humans, the full-length transcript encoding Darpp-32 is sometimes detected in normal, healthy epithelial tissue. t-Darpp, on the other hand, is rarely expressed [3]
Summary
Darpp-32 and t-Darpp are expressed in several forms of breast cancer. Both are transcribed from the gene PPP1R1B via alternative promoters. Darpp-32 is a well known regulator of neurotransmission, its role in other tissues and in cancer is less well understood. T-Darpp is known to increase cellular growth, inhibit apoptosis and contribute to acquired drug resistance. T-Darpp’s mechanism of action is not known, but it has reported activity for increasing cell growth, inhibiting apoptosis, and promoting drug resistance in cancer cells [11,12,13,14,15,16,17] The truncated t-Darpp protein lacks 36 amino acids at the N-terminus, including a phosphorylation site critical to the function of Darpp-32 as a phosphatase inhibitor [2,9,10]. t-Darpp’s mechanism of action is not known, but it has reported activity for increasing cell growth, inhibiting apoptosis, and promoting drug resistance in cancer cells [11,12,13,14,15,16,17]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have